Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage Defects

Inclusion Criteria: 1. 50 years to 65 years 2. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate in the clinical trial and sign the consent form 3. Subjects with localized full-thickness cartilage defects in the knee joint, International Cartilage Repair Society(ICRS) Grade III or IV 4. Subjects whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms 5. knee cartilage defect size :1.5cm\^2 to 10cm\^2 Exclusion Criteria: 1. Patients who have autoimmune diseases (Ex. Rheumatoid arthritis) 2. When screening, Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (However, arthroscopy for diagnostic purposes is possible. Additionally, it is possible if hightibial osteotomy (HTO) has been performed in advance or is scheduled) 3. When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 1 month 4. When screening, Patients who took oral steroid within 2 weeks 5. Patients who can't take MRI scan 6. BMI index : 30kg/m\^2 or over 7. Patients who have gout or gout history in the knee 8. Women who are pregnant or breast-feeding, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception. 9. Patients with risk factor for bleeding 10. Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial